@article{25904,
  author = {Pechalrieu D and Lopez M},
  title = {Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).},
  abstract = {<p>Tuberculosis is one of the main causes of mortality with 1.5 million deaths a year worldwide. The growing emergence of multi- and extremely resistant strains highlights the urgent need of novel antibiotic strategies. Ethionamide, interfering with the mycobacterial membrane biosynthesis, is used in second-line treatment. This molecule is a prodrug, which requires activation by EthA. The patent described in this evaluation (WO2014049107A1) claimed a new family of molecules and their use as antibiotic treatment against mycobacteria such as Mycobacterium tuberculosis, M. leprae and atypical mycobacteria, either as a single active agent or in combination with antibiotics activable by EthA pathway.</p>
},
  year = {2015},
  journal = {Expert opinion on therapeutic patents},
  pages = {1-7},
  issn = {1744-7674},
  doi = {10.1517/13543776.2015.1021333},
  language = {eng},
}